Insulet (NASDAQ:PODD) was upgraded by stock analysts at BidaskClub from a “sell” rating to a “hold” rating in a research note issued on Wednesday, BidAskClub reports.

Other analysts also recently issued reports about the company. Northland Securities restated a “buy” rating and issued a $100.00 price objective on shares of Insulet in a report on Tuesday, February 26th. Canaccord Genuity increased their price target on Insulet from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Tuesday, February 19th. ValuEngine downgraded Insulet from a “strong-buy” rating to a “buy” rating in a research note on Monday, January 7th. Morgan Stanley reduced their target price on Insulet from $105.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, January 2nd. Finally, Oppenheimer set a $100.00 price target on shares of Insulet and gave the company a “hold” rating in a research report on Tuesday, February 26th. Four investment analysts have rated the stock with a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $103.20.

Insulet stock opened at $86.08 on Wednesday. Insulet has a 12 month low of $70.80 and a 12 month high of $108.90. The company has a debt-to-equity ratio of 2.79, a quick ratio of 3.37 and a current ratio of 3.99. The company has a market capitalization of $5.14 billion, a PE ratio of 1,721.60 and a beta of 1.51.

Insulet (NASDAQ:PODD) last issued its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.01 by $0.06. Insulet had a return on equity of 1.73% and a net margin of 0.58%. The business had revenue of $159.56 million for the quarter, compared to the consensus estimate of $154.66 million. During the same quarter in the prior year, the business posted ($0.11) earnings per share. The firm’s quarterly revenue was up 29.1% compared to the same quarter last year. On average, analysts anticipate that Insulet will post 0.23 EPS for the current year.

In other Insulet news, insider Shacey Petrovic sold 1,066 shares of the stock in a transaction that occurred on Wednesday, March 6th. The shares were sold at an average price of $92.64, for a total value of $98,754.24. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP David Colleran sold 7,395 shares of the stock in a transaction that occurred on Tuesday, April 2nd. The stock was sold at an average price of $94.89, for a total transaction of $701,711.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 87,138 shares of company stock worth $8,140,640. Corporate insiders own 3.50% of the company’s stock.

Several large investors have recently modified their holdings of PODD. Norges Bank bought a new stake in shares of Insulet in the 4th quarter worth about $53,604,000. First Trust Advisors LP grew its position in Insulet by 103.6% during the 4th quarter. First Trust Advisors LP now owns 458,028 shares of the medical instruments supplier’s stock worth $36,331,000 after purchasing an additional 233,075 shares during the last quarter. Standard Life Aberdeen plc purchased a new stake in Insulet during the 4th quarter worth approximately $16,011,000. Teachers Advisors LLC lifted its stake in shares of Insulet by 105.8% in the 3rd quarter. Teachers Advisors LLC now owns 326,021 shares of the medical instruments supplier’s stock valued at $34,542,000 after purchasing an additional 167,598 shares during the period. Finally, KAMES CAPITAL plc lifted its stake in shares of Insulet by 22.7% in the 1st quarter. KAMES CAPITAL plc now owns 582,252 shares of the medical instruments supplier’s stock valued at $55,372,000 after purchasing an additional 107,828 shares during the period.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes in the United States and internationally. The company offers Omnipod Insulin Management System (Omnipod System), which consists of an easy-to-use continuous insulin delivery system; and Personal Diabetes Manager, a handheld wireless device.

Recommended Story: Convertible Shares

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.